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Interindividual variation in the concentration of plasma lipids which are associated with coronary artery
disease (CAD) risk is determined by a combination of genetic and environmental factors. This study
investigates the effects of apoE genotype and plasma concentration on cholesterol and triglycerides (TG)
levels in subjects from five countries: Finland, France, Northern Ireland, Portugal, and Spain. Age and sex
significantly influenced serum cholesterol, TG and apoE concentrations. The age effect differs in males
and females. The allele frequencies of the apoE gene, one of the most widely studied CAD susceptibility
genes, were determined: the e2 allele frequency and the apoE concentration showed a north – south
increasing gradient while the e4 allele frequency showed the reverse. ApoE plays an important role in
lipid metabolism. Total cholesterol and TG concentrations were significantly dependent on apoE
genotype in both sexes. These differences in lipids between genotypes were more pronounced when
plasma apoE concentrations were taken into account.
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Introduction
CAD is one of the main causes of mortality and morbidity
in developed countries. Several major risk factors for ather-
osclerosis have been identified; age, gender, hyper-
cholesterolaemia, hypertriglyceridaemia, hypertension,
diabetes and smoking.
Genetic factors in combination with environment play
an important role in the etiology of CAD.1 It is known that
the genetic polymorphism of apolipoprotein E (apoE)
modulates lipoprotein metabolism and thereby influences
CAD risk factors. ApoE is probably the most studied
susceptibility gene for atherosclerosis and CAD. There are
three common alleles of the apoE gene (e2, e3 and e4). This
polymorphism results in six genotypes, three heterozygote
e3/e2, e3/e4, e4/e2 and three homozygote genotypes e2/e2,
e3/e3 and e4/e4.2 The alleles encode isoforms of apoE, which
differ in terms of their interaction with cell surface recep-
tors, and catabolism of apoB-containing lipoproteins.
In the population at large, the e2 allele is associated with
lower and the e4 with higher total cholesterol than the e3
allele. In some studies the e2 and the e4 alleles have beenReceived 15 January 2002; revised 31 May 2002; accepted 28 June 2002
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reported to be associated with high triglycerides levels.3 – 5
Nevertheless the role of apoE polymorphism in neither
cholesterol nor triglycerides metabolism has been fully
elucidated. It also influences the plasma concentration of
apoE6 and apoB. The serum apoE concentration is highest
in e2 carriers and lowest in e4 carriers.7 The plasma apoB
concentration shows the opposite pattern, it is lowest in
subjects heterozygous for apoE 2 and highest in E4/4
subjects.8
Several studies have demonstrated that the apoE poly-
morphism is associated with the risk of CAD.9 However,
the antiatherogenic effect of apoE is not entirely mediated
through lipid metabolism, as it may also have a local effect
on the arterial wall and on cellular regulation. The purpose
of this study was to investigate the role of apoE genotypes
and plasma concentration as risk markers for disease. Our
investigations have been realised, thanks to the ApoEurope
project.
The objective of the ApoEurope project is to establish the
usefulness of apoE genotype and concentration in health
and diseases. The specific objectives are: (1) to determine
the factors affecting interindividual variation in apoE plas-
ma concentration, particularly the role of apoE genetic
polymorphism; (2) To study the distribution of apoE geno-
type/apoE plasma concentration across different European
populations; (3) To evaluate , in case-control studies, the
role of apoE plasma concentration together with apoE
genotype as risk factors for: coronary artery disease and
alzheimer disease. More details on ApoEurope project are
given by Schiele et al.7
Our study presents a useful element for going deeper in
the different steps of the ApoEurope project by investigat-
ing the combined usefulness of the apoE genotype and
concentration.
Materials and methods
Subjects
Subjects from different geographic regions of Europe were
selected for participation in the ApoE-Europe project (Part
I). More details on ApoEurope project are given by
Schiele et al.7 Five centres, Helsinki (Finland), Belfast
(Northern Ireland), Nancy (France), Lisbon (Portugal),
and Barcelona (Spain) participated. Persons taking lipid-
lowering drugs were excluded. The total number of
subjects participating was 6207; consisting of 3267 men
and 2940 women aged between 25 – 64 years. All partici-
pants were considered as being free from serious and/or
chronic illnesses (Alzheimer disease, CHD . . .) at the time
of the recruitment. Each participant filled specific ques-
tionnaires concerning their state of health. Recruitment
was done according to the ethic rules of each country
participating in the study: when needed each participant
gave their informed consent for participating in the
different studies, which were approved by the ethic
committee of each centre.
In Finland, the subjects were a sub-sample of the third
Finmonica10 risk factor survey carried out from January –
March 1992. These participants were men and women
aged 45 – 64 years. In Northern Ireland, the participants
were male volunteers aged between 30 – 54 years from a
large Belfast based work-force, and included all grades of
staff from manual to clerical and administrative workers.
In France, the participants were derived from the Stani-
slas11 cohort, a sample from the general population
living in the Vosges region and the centre of Meurthe-et-
Moselle. One thousand and six families consisting of two
parents and at least two of their biological children were
selected. All participants were of European origin. They
were considered as being free from serious and/or chronic
illnesses. The parents included were aged from 25 to 64
years. In Portugal, the sample consisted of those attending
different laboratories of the National Institute of Health of
Lisbon, aged between 25 and 64 years. Subjects were
invited daily in a random fashion, from those who were
present at the blood collection from 8.30 to 10.00 am.
AIDS seropositives persons were excluded. All participants
were considered healthy. In Spain, the population base
was the Monica12 area of Barcelona, which had a total
population of over 1 000 000 inhabitants. The area is repre-
sentative of the whole region of Catalonia. The sample,
stratified by age and sex, was drawn from the municipal
population registers. The subjects selected were aged from
25 to 64 years.
Blood samples
In Finland, subjects were requested to fast for 4 hours
before taking the blood samples, which were then centri-
fuged at 1400 g for 30 min at room temperature. Serum
was divided in 0.5 ml aliquots before freezing; samples
were kept at 7708C until analysed. In Northern Ireland,
20 ml of venous blood was collected after a 6 h fast. Ten
ml was anticoagulated with EDTA and 10 ml allowed to
clot at room temperature in the dark. In France, blood
samples were collected after an overnight fast, either in
EDTA for DNA preparation or in vacutainer tubes contain-
ing a gel for serum separation (Becton Dickinson). Blood
was centrifuged promptly at 1000 g for 15 min at room
temperature for serum and buffy coat preparation. The sera
and buffy coats were stored at 71968C. In Spain, blood
was collected after an overnight fast (10 – 12 h) in vacutai-
ner tubes without anticoagulant. Blood was centrifuged at
+48C at 2500 g for 15 – 20 min. Samples were transported
at +48C to the central laboratory where they were stored
at 7808C. In Portugal, after an overnight fast, blood was
collected in vacutainer tubes, one containing EDTA for
DNA extraction and the other containing a separating gel
without anticoagulant for serum separation. Samples were
stored at 7708C.
The designs of blood sampling and storage conditions
used in the different centres are summarised in Table 1.
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Lipid measurements
The measurements of the different parameter concentra-
tions were done in France. Specific tests showed that fresh
and frozen samples have no significant differences on lipid
levels. Storing at 770 to 71968C temperatures did not
affect the samples.
Total cholesterol and triglycerides were measured using
enzymatic methods on an automated analyser (Roche Diag-
nostics). ApoE concentrations were determined by
immunoturbidimetry according to the manufacturer’s
recommendations, using a kit from Daiichi (number
114861).7 Sera were analysed without pre-treatment and,
when apoE concentration exceeded 100 mg/l, diluted in
double-distilled water.
Apolipoprotein E genotyping and phenotyping
DNA extraction from whole blood or buffy coat was
performed using a salting-out procedure.13 ApoE genotype
was determined by PCR amplification and subsequent
digestion with HhaI restriction enzyme, as described by
Hixson and Vernier.14 ApoE phenotyping was determined
by isoelectrofocusing and immunoblotting.
Statistical methods
The distribution of the apoE alleles was tested for Hardy –
Weinberg equilibrium by w2 testing. Adjustment of mean
cholesterol and triglycerides levels for age and centre was
done by analysis of covariance. Because of the skewness
of the triglycerides distribution, logarithmic transforma-
tions were applied in order to meet the model
assumptions. Multiple regression analyses were performed
to study the simultaneous independent contribution of
the apoE polymorphism and concentrations with age,
body mass index, current smoking and contraceptive pill
use as covariates. In view of the non-linear effect of age
on cholesterol levels, a quadratic term for age was intro-
duced in the models. Regression assumptions were
visually checked through the Pearson residuals. An a priori
level of a=0.05 was chosen to indicate statistical signifi-
cance. All analyses were performed using SAS software
(version 6.12).
Results
Table 2 presents the observed distribution of apoE geno-
types among the participants by centre separately for men
and women. The distributions of the apoE alleles were in
Hardy – Weinberg equilibrium. The frequencies of e2 and
e4 alleles showed a significant difference across centres. As
reported before,7 the e2 allele frequency followed a north-
south increasing gradient while the e4 allele showed the
reverse.
In Table 3, the distributions of plasma cholesterol, trigly-
cerides and apoE concentrations are shown by age group,
centre and apoE genotype for men and women separately.
The total cholesterol levels generally rose with age but
seemed to level off after the age of 54 years in both sexes.
The influence of age on triglycerides concentrations was
fairly linear. We observed a sex-differential effect of age
on mean apoE concentrations as in men apoE concentra-
tions are leveled off after the age of 45 years, whereas
they are continuously rising with age in women.
In order to correct for differences in the age distributions,
the means for the several centres and genotypes, as well as
the overall sex-specific means, were age-adjusted. In gener-
al, total cholesterol and triglycerides levels were higher in
men than in women. Also, there was a tendency towards
higher average apoE concentrations in men compared to
women. As expected, the subjects from the northern coun-
tries: Finland, Northern Ireland and France, had higher
mean cholesterol concentrations than those from the
Southern countries: Portugal and Spain, a consistent obser-
vation in both sexes. A geographical trend among the five
populations was less obvious for serum triglycerides, with
the lowest age-adjusted averages in French men and women
and the highest levels in Northern-Ireland and Spain. For
both sexes, there was a clear tendency for higher mean
apoE concentrations in the southern centres. This trend
seemed to be broken only by the high apoE concentrations
in men from Northern Ireland.
We observed the lowest cholesterol concentrations
among e2 carriers, while the e4 allele seems to be associated
with higher cholesterol levels. The e4/e4 homozygotes had
the highest mean concentration of cholesterol in both sexes
Table 1 Design of blood sampling and storage conditions used in the five centres
Centres Finland Northern Ireland France Spain Portugal
Sampling
Number 2037 672 1871 1009 618
Sex Men and women Men Men and women Men and women Men and women
Fasting 54 h 56 h 12 h 12 h 12 h
Posture Sitting Sitting Supine Sitting Supine
Period 1992 – 1992 1994 – 1995 1993 – 1995 1993 – 1994 1996 – 1997
Storage
Duration (up to) 5.5 years 2.6 years 1.5 years 3 – 4 years 6 months
Temperature 7708C 7808C 71968C 7808C 7708C
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(6.06 mmol/l in men and 6.02 mmol/l in women) whereas
the e2/e2 homozygotes had the lowest levels in women
(4.52 mmol/l), and nearly so in men (5.59 mmol/l). Hetero-
zygosity (e3/e2, e3/e4 and e2/e4) was associated with
intermediate concentrations. As the apoE concentration
proved to be highly allele-dependent, as seen in Table 3,
this association between apoE polymorphism and cholester-
ol levels may be confounded by the apoE concentration.
Therefore, mean cholesterol levels were additionally
adjusted for the apoE concentration. As can be seen in
Figure 1a, the impact of the apoE polymorphism on total
cholesterol levels was even more striking when apoE
concentrations were taken into account. After adjusting
for age and centre only, the mean cholesterol levels were
only moderately different between the apoE genotypes.
However, with additional adjustment for the apoE concen-
tration, the differences became huge, proving the crucial
confounding impact of the apoE concentration in interpret-
ing the role of the apoE polymorphism in explaining the
inter-individual variability in cholesterol levels. In order
to explain the variability of the cholesterol concentrations
in more detail, results of fitting three nested multiple
regression models for both sexes are presented in Table 4.
Age was modeled as a linear and quadratic effect because
of its curvilinear relation to total cholesterol levels. Introdu-
cing the apoE concentrations in the model had a
fundamental impact on the percentage of explained
variance (model C). The apoE polymorphism alone (model
B) was responsible only for a moderate 2% increase in
explained variance of cholesterol levels in both men and
women. Moreover, these results confirm the important role
of the apoE concentrations in interpreting differences in
mean cholesterol levels between genotypes. For example,
without additional adjustment for apoE concentration, in
men the differences in mean cholesterol between the 2/2
and 3/3 and between 4/4 and 3/3 genotypes were
70.155 mmol/l and +0.166 mmol/l respectively (both not
significant, model B). However, additional correction for
the apoE concentration changed these differences to respec-
Table 2 Frequency of apoE genotype and apoE allele by centre and sex
Finland Northern Ireland France Portugal Spain
Men Women Men Women Men Women Men Women Men Women
Genotype
e2/e2 0 1 0 – 5 7 1 1 5 3
e3/e2 75 118 60 – 131 134 29 38 46 69
e3/e3 526 548 395 – 577 577 156 276 286 302
e4/e3 249 260 171 – 166 191 38 54 80 98
e4/e2 27 19 7 – 14 26 2 4 5 5
e4/e4 25 32 11 – 13 17 1 7 4 3
Allele
e2 0.057 0.071 0.052 – 0.085 0.090 0.073 0.058 0.071 0.083
e3 0.77 0.75 0.79 – 0.80 0.78 0.83 0.085 0.82 0.80
e4 0.18 0.17 0.15 – 0.11 0.13 0.09 0.09 0.11 0.11
Table 3 Mean total cholesterol, triglycerides and apoE
concentrations by sex, age and centre
Total ApoE
cholesterol Triglycerides concentration
n (mmol/l) (mmol/l) (mg/l)
Men
25 – 34 years 378 5.32 1.11 38.5
35 – 44 years 1174 5.88 1.25 40.7
45 – 54 years 1064 6.00 1.34 40.8
55 – 64 years 651 5.84 1.33 40.2
Finland 970 5.82 1.28 36.9
N-Ireland 672 6.00 1.49 43.0
France 915 6.00 1.14 39.6
Portugal 232 5.59 1.24 44.3
Spain 478 5.54 1.30 44.1
e2/e2 11 5.59 1.44 73.9
e3/e2 341 5.50 1.30 47.3
e3/e3 1940 5.84 1.23 39.6
e4/e3 704 6.04 1.35 38.9
e4/e2 45 5.82 1.43 46.8
e4/e4 54 6.06 1.35 37.0
All men 3267 5.85 1.28 40.4
Women
25 – 34 years 292 5.05 0.83 36.0
35 – 44 years 921 5.39 0.81 37.0
45 – 54 years 991 5.63 0.95 38.6
55 – 64 years 736 5.20 1.15 42.6
Finland 1067 5.59 0.94 35.6
N-Ireland 0 – – –
France 956 5.87 0.86 38.1
Portugal 386 5.54 0.99 42.7
Spain 531 5.39 1.01 44.3
e2/e2 12 4.52 1.05 59.4
e3/e2 359 5.34 1.08 45.3
e3/e3 1703 5.60 1.10 38.4
e4/e3 603 5.88 1.04 35.8
e4/e2 54 5.50 1.15 47.0
e4/e4 59 6.02 1.02 31.6
All women 2940 5.64 0.94 38.8
Note: means by centre, apoE genotype and sex are age-adjusted.
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tively 71.365 mmol/l (2/2 vs 3/3) and +0.284 mmol/l (4/4
vs 3/3), both being statistically significant (model C). From
the estimated centre-specific regression coefficients we also
can conclude that differences in cholesterol distributions
between centres were altered when the apoE polymorphism
and concentration are taken into account. Interestingly, the
effect of BMI on cholesterol levels dropped in both sexes
when adding the apoE concentration to the model. In
women, the impact of contraceptive pill use on total
cholesterol levels was 10-fold higher when the apoE
concentrations were taken into account.
We also studied the variability of triglycerides levels as
a function of the apoE genotype. We found very similar
results (Table 5), as differences in mean triglycerides
between apoE genotypes were much more pronounced
when the apoE concentration was considered (Figure
1b). In both sexes, additional correction for the apoE
concentration resulted in a decrease in mean triglycerides
levels in the presence of the e2 allele and an increase in
e4 subjects. The triglycerides concentrations of the e2/e2
genotype carriers decreased in men from 1.52 to
0.47 mmol/l and in women a decrease was noted from
1.07 to 0.70 mmol/l. In e4/e4 homozygotes, the triglycer-
ides concentrations rose from 1.34 to 1.39 mmol/l in
men and from 1.02 to 1.12 mmol/l in women (Figure
1b). Biological factors such as age, BMI, tobacco consump-
tion and geographic location, explained 14 and 23%,
respectively of inter-individual variability of triglycerides
concentrations in men and women. Adding in the apoE
genotype only explained an extra 1% in men and women.
The apoE concentration had a supplementary contribu-
tion resulting in explained variances of 51% in men
and 39% in women.
Discussion
Adverse levels of serum lipids are predictive of CAD. In the
Program On the Surgical Control of the Hyperlipidaemias
(POSCH),15 Scandinavian Simvastatin Survival Study
(4S),16 Cholesterol And Recurrent Events (CARE)17 and West
of Scotland Coronary Prevention Study studies
(WOSCOPS),18 total plasma cholesterol and triglycerides
values were positively correlated with cardiovascular risk.
The understanding of the inter-individual variabilities of
cholesterol and triglycerides plasma concentrations is useful
for the prediction and for the treatment of these diseases.
In the majority of cases, an individuals risk of developing
CAD is the consequence of complex interactions of many
genetic and environmental factors.19
In our study, age and sex significantly influence serum
cholesterol, triglycerides and apoE concentrations. We
found lower mean values in women than in men. Age
effects differed between males and females beyond 45 years;
cholesterol, TG and apoE concentrations were quite steady
in men but continue to increase with age in women.
Gender-specific factors, such as hormonal status, could be
responsible for these gender differences. Sex hormones are
known to have multiple effects on lipoprotein metabolism.
The shortened retention time of apoE in very low density
Table 4 Estimated regression coefficients in several models for total cholesterol
Men Women
Model A Model B Model C Model A Model B Model C
b b b b b b
Age 0.194c 0.192c 0.124c 70.048a 70.047a 70.034
Age2 70.002c 70.002c 70.001c 0.001c 0.001c 0.001c
BMI 0.036c 0.035c 70.004 0.020c 0.021c 0.001
Smoking 0.134b 0.140b 0.103b 0.075 0.071 0.068
Contraceptive drugs use – – – 0.012 0.044 0.312c
Centre (vs France)
Finland 70.246c 70.293c 70.124a 70.347c 70.380c 70.208c
N-Ireland 70.038 70.073 70.225c – – –
Portugal 70.394c 70.399c 70.612c 70.388c 70.396c 70.581c
Spain 70.529c 70.546c 70.714c 70.536c 70.514c 70.699c
ApoE genotype (vs 3/3)
2/2 – 70.155 71.365c – 71.028c 71.810c
3/2 – 70.363c 70.713c – 70.262c 70.579c
4/3 – 0.186c 0.217c – 0.276c 0.374c
4/2 – 70.054 70.390b – 70.136 70.542c
4/4 – 0.166 0.284a – 0.423c 0.722c
Ln(ApoE concentration) – – 1.972c – – 1.750c
R2 8% 10% 34% 18% 21% 38%
aP50.05 bP50.01 cP50.0001. Model A: includes age, age2, BMI, smoking, contraceptive drugs use for women, and centre. Model B: model
A+apoE genotype. Model C: model B+ln(apoE concentration). b: estimated regression coefficient. R2: % explained variance in cholesterol levels.
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lipoprotein (VLDL) associated with the presence of oestro-
gen, as reported in animal studies, suggests that oestrogen
influences VLDL clearance.20
Schiele et al7 found that serum apoE concentration contin-
ued to increase in women aged over 50 years, and related this
to hormonal changes at the menopause. Indeed the effect of
menopause is frequently studied and is known to be a cardi-
ovascular risk factor.21,22 The effect of sex hormones in
interaction with age could explain the differences in apoE
concentration between men and women observed in the
literature. Indeed, in some studies it has been demonstrated
that apoE concentration was higher in women,23 in others,
apoE concentration was higher in men24 or even no differ-
ence between men and women was observed.25
We have shown that in northern countries (Finland, N-
Ireland and France) women or men had mean cholesterol
and triglycerides concentrations higher than those of the
southern countries. One important finding suggested the
existence of an increasing north – south gradient in the
serum apoE concentration throughout Europe, and this
has already been described by Schiele et al.7
The frequencies of the apoE alleles differ among popu-
lations, ranging from 0.052 to 0.09 for e2, 0.75 to 0.85 for
e3 and 0.09 to 0.18 for e4. We observed significant differ-
ence in the distribution of the apoE alleles in the five
participating centres: e2 allele follows a north – south
increasing gradient but the e4 allele went in the opposite
direction. This is in line with previous reports of a higher
frequency of the e4 allele in northern than in southern
Europe.4,26
Our study and other groups, such as Schaefer7,27 have
already shown significant associations between plasma apoE
concentration and apoE isoforms. Here, in a large European
study, this correlation of apoE genotype with plasma apoE
concentration was better defined in both men and women.
This association was highly significant (P50.0001), and
indicates that the apoE locus is a major factor controlling
apoE concentration in plasma.7 Thus, the apoE concentra-
tion could mask the effect of genotype.
The apoE allele effect on serum cholesterol levels is
similar in most populations. Differences in ethnic origin
and/or lifestyle factors could explain the non-significant
impact of all the genotypes on the variability of total
cholesterol in Portugal (men) and in Spain (men and
women). This result is in agreement with that of a Spanish
team who found that the influence of apoE on plasma
cholesterol was not significant in men.28 Conflicting
results for triglycerides levels are found in the literature.
Since triglycerides vary widely among individuals,3 this
variability could mask a clear apoE genotype effect.
Dallongeville et al. (1992),6 as in other studies,4,5 docu-
mented a significant association between apoE2 and
apoE4 and higher triglycerides levels compared to e3/e3
homozygotes.
Different apoE isoforms show different affinities to the
LDL receptors,29 as reported for the apoE4 which has a
higher affinity than apoE3,30,31 but the apoE2 has markedly
lower binding affinity in comparison to apoE3. In addition,
apoE isoforms influence the location of apoE in lipopro-
teins, eg apoE4 is preferentially located in VLDL, apoE3
Table 5 Estimated regression coefficient in several models for total triglycerides
Men Women
Model A Model B Model C Model A Model B Model C
b b b b b b
Age 0.045c 0.044c 0.016 70.017 70.019a 70.012
Age2 70.00045c 70.00045c 70.00016 0.00031b 0.00032c 0.00020a
BMI 0.049c 0.049c 0.029c 0.036c 0.036c 0.028c
Smoking 0.135b 0.136c 0.111c 0.106c 0.106c 0.104c
Contraceptive drugs use – – – 0.257c 0.259c 0.362c
Centre (vs France)
Finland 0.052 0.053 0.125c 0.038 0.035 0.105c
Portugal 0.077 0.080a 70.042 0.113c 0.122c 0.035
Spain 0.08a 0.084b 70.023 0.104c 0.113c 0.029
ApoE genotype (vs 3/3)
2/2 – 0.245 70.842c – 0.190 70.202
3/2 – 0.058 70.139c – 0.017 70.122c
4/3 – 0.081b 0.078c – 0.070b 0.106c
4/2 – 0.095 70.045 – 0.230c 0.045
4/4 – 0.012 0.054 – 0.116a 0.218c
Ln(ApoE concentration) – – 0.026c – – 0.019c
R2 14% 15% 51% 23% 24% 39%
aP50.05 bP50.01 cP50.0001. Model A: includes age, age2, BMI, smoking, contraceptive drugs use for women, and centre. Model B: model
A+apoE genotype. Model C: model B+ln(apoE concentration). b: estimated regression coefficient. R2: % explained variance in cholesterol levels.
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and apoE2 in HDL.32 As a consequence, e2 has been esti-
mated to decrease LDL cholesterol by 12.5% and HDL
cholesterol by 3.1%, as compared to e3. Individuals with
e4, have higher concentrations of both LDL cholesterol
and HDL cholesterol with estimated increases of 6.4% and
1.9%, respectively.33
The inter-individual variability in cholesterol and TG
levels can be explained by environmental factors (age,
sex, etc. . .), genetic factors such as the apoE polymorphism
and apoE concentration. It seems that apoE affects choles-
terol levels similarly in different populations despite
different allelic frequencies.34
a
b
Figure 1 (a) Means of total cholesterol by apoE genotype and sex adjusted for centre and age, and before and after additional
adjustment for apoE concentration. (b) Means of plasma triglycerides by apoE genotype and sex adjusted for centre and age, and before
and after additional adjustment for apoE concentration.
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Geographic location, body mass index, tobacco smoking
and contraceptive pill use in women, explained 8 and 18%
of the inter-individual variability of cholesterol concentra-
tion in men and women respectively. The apoE
polymorphism alone was only responsible for a modest
2% higher explained variance of cholesterol levels in both
sexes. The addition of the apoE concentration enabled us
to explain 34 and 38% of this variability in men and in
women, respectively. The combined effects of the apoE
polymorphism and apoE concentration could explain the
cholesterol variability better. In another study, we have
also observed that apoE genotype and apoE concentration
can explain 27% of the variability of the cholesterol
level.35
This result, reported again in this study is as important to
our knowledge as it was the first time, namely, that apoE
polymorphism and concentration has been used to explain
the inter-individual variability of cholesterol levels. This
confirms our earlier study30 with cellular models where
we showed that in addition to apoE polymorphism, apoE
concentration was an important factor in determining
VLDL binding to HepG2 cells surface receptors.
This explained 51 and 39% of the TG level variability
in men and women, respectively. Biological factors such
as age, BMI, tobacco consumption and geographic
regions, explained 14 and 23% at the inter-individual
variability of triglycerides concentrations in men and
women respectively. ApoE polymorphism and concentra-
tion together explain triglycerides levels by 15% in men
and 24% in women (taking only the apoE genotype into
account) to 51 and 39% in men and in women respec-
tively (taking the apoE genotype and concentration into
account).
The total of variance of triglycerides was, 0.26 in women,
and 0.68 in men; of this variance, about 22.75% women
and 46.28% in men was explained by apoE concentration
and apoE/LPL polymorphism.36 ApoE concentration was
positively correlated with triglycerides and apoE levels
explained about 42% of triglycerides variability in a
Chinese CAD group.35
In conclusion, the results presented in this study are very
important because they allow confirmation in large
European populations of the north – south gradient of the
apoE alleles frequencies and apoE concentration already
described by us and others.
Most importantly, for the first time, the cholesterol and
triglycerides inter-individual variability are investigated in
relation with apoE polymorphism and apoE concentration,
simultaneously, in large size samples and within different
European populations.
Moreover, the study demonstrated not only that apoE
polymorphism together with apoE concentration explained
a big percentage of cholesterol and triglycerides variability
but also that apoE concentration could mask the apoE poly-
morphism effect.
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